| 51. | | | Flowability of Pharmaceutical Powders: Impact of Humidity
|
| 52. | | | Formulation and Complex Morphological Characterization of Core-Shell Fibrous Mats for Chronic Wound Healing
|
| 53. | | | Formulation and Investigation of Gels Containing Spirulina Powder
|
| 54. | | | Formulation and Physiochemical Characterization of NLC-miRNA Complexes
|
| 55. | | | Formulation of Apigenin-Loaded Liposomes for Pulmonary Delivery
|
| 56. | | | Formulation of Baicalin-loaded Self-nanoemulsifying Matrix Pellets
|
| 57. | | | Future of the Hungarian Drug Market - Role of the Hungarian Regulatory Authority
|
| 58. | | | GGlobal Biosimilar Drug Development: Any Chance for Consolidation after 15 Years of Positive Regulatory Experience?
|
| 59. | | | Glycopeptide Antibiotic Derivatives Against Resistant Bacteria
|
| 60. | | | The Gut in a Beaker: More Challenges for In Vitro Testing
|
| 61. | | | High-Through put Screening for Bioactive Natural Compounds from Plant Extracts by HPTLC Hyphenations
|
| 62. | | | A HILIC-MS/MS Method for the Structural Analysis of Human Alpha-1-Acid Glycoprotein
|
| 63. | | | How Should Synthetic Follow-Ons of Biological Products Be Regulated? What Are the Implications for Automatic?
|
| 64. | | | How to Deal with Complexity of Nanomedicine in Practice
|
| 65. | | | Hydrocolloid Gel-Formers and Polyvalent Cations in the Formation of Microparticles
|
| 66. | | | Image Analysis: A Novel Method in the Assessment of Pharmaceutical Foams
|
| 67. | | | Impact of one High Dose of Ceftazidime Administrated before Minimally Invasive Multimodal Endoscopic Prostate Surgery
|
| 68. | | | Industry Perspectives in Modern Drug Research and Development Strategies
|
| 69. | | | Insights for a Risk-Assessment Tool to Manage Medicines Shortages
|
| 70. | | | Interfacial Properties of Biodegradable Drug Carrier Nanoparticles
|
| 71. | | | International Conference on Advances in Pharmaceutical Drug Development, Quality Control and Regulatory Sciences: DDRS 2021: Budapest, 15-17. November 2021.
|
| 72. | | | Investigating the Influence of Heat Stress to the Activity And Structural Changes of Lactase Enzyme
|
| 73. | | | Investigation of the Drug Dose, Alongside the Solubility, the Permeability, and their Interplay, as Key Factors in Formulation Development for Oral Lipophilic Drugs
|
| 74. | | | Is the Multi-Attribute Method (MAM) the Next Big Thing? : A High-Resolution Accurate Mass Multi-Attribute Method for Critical Quality Attribute Monitoring
|
| 75. | | | Isolation and Analysis of Human Urinary Marker Protein uAGP by Liquid Chromatographic Methods
|
| 76. | | | Lipopeptide Nanoparticulate Vaccine Candidates for the Induction of Protective Immune Responses
|
| 77. | | | Merging Science and Patient in Future Drug Development to Enhance Safety and Effectiveness
|
| 78. | | | Metabolomic Characterization of Newest Designer Drugs
|
| 79. | | | The Molecule that Shaped the History of Western Civilization
|
| 80. | | | mRNA-Lipid Nanoparticle COVID-19 Vaccines: Structure and Stability
|
| 81. | | | Nano-amorphous Oral Sirolimus Formulation with Improved Exposure and Low Inter-individual Variability
|
| 82. | | | Newest Techniques in the Investigation Procedure of Counterfeit/Illegal Medicinal Products
|
| 83. | | | Novel E3 Ligase Ligand Libraries for Degradation of Proteins Implicated in Malignant Diseases
|
| 84. | | | Novel fluorescent Labelled, Pegylated Prussian Blue Nanoparticles for in vivo Optical Imaging
|
| 85. | | | Novel magnetic Prussian Blue nanoparticles for in vivo T1 MR-imaging
|
| 86. | | | Pharmacological Overview of the Drug Candidate BGP-15
|
| 87. | | | Physical Chemical Analysis of Fullerene Aqueous Dispersions
|
| 88. | | | The Place of Science in the "One FIP Strategy"
|
| 89. | | | Possible Metabolic Transformation of Pinenes to Ionones
|
| 90. | | | Potential Mechanisms Involved in Sphingosine-1-phosphate Induced Coronary Flow Reduction
|
| 91. | | | Preformulation Studies on Polymeric Nanocapsules
|
| 92. | | | Prodrug Nano-Squalene Bioconjugate Drug Products
|
| 93. | | | Project Orbis - New Regulatory Pathway for Innovative Oncology Therapies
|
| 94. | | | Regulatory Pathway for Drug-Device Combination Products in US
|
| 95. | | | Regulatory Perspectives - Where We Came from, Where Are We Today, Where Are We Headed?
|
| 96. | | | Regulatory Science Challenges - Encouraging Innovation Through an Adaptive Regulatory System
|
| 97. | | | Regulatory Science in Drug Development
|
| 98. | | | The Relations Between Q3 Measurements, In vitro Release and TCS
|
| 99. | | | Revolutionary Application of 3D-Two-Photon Microscopes for Human Therapy and Drug Research
|
| 100. | | | Rheological Studies of Hydrogels and Liposomal Dispersions: Factors Influencing the Viscoelastic Properties
|
